ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06070948
- Locations
- ๐บ๐ธ
Acpru /Id# 259897, Grayslake, Illinois, United States
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06068842
- Locations
- ๐ฏ๐ต
Kindai University Hospital /ID# 257890, Osakasayama-shi, Osaka, Japan
๐จ๐ญUniversity Hospital Zurich /ID# 256678, Zurich, Zuerich, Switzerland
๐จ๐ณNational Taiwan University Hospital /ID# 261542, Taipei City, Taipei, Taiwan
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06068868
- Locations
- ๐บ๐ธ
University of Chicago Medical /ID# 252764, Chicago, Illinois, United States
๐บ๐ธCity of Hope /ID# 253727, Duarte, California, United States
๐บ๐ธUniversity of California Davis Health /ID# 252723, Sacramento, California, United States
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 249
- Registration Number
- NCT06068855
- Locations
- ๐ง๐ช
Da Vinci Clinic /ID# 246731, Beerse, Antwerpen, Belgium
๐ง๐ชEvolve Clinic /ID# 246729, Schilde, Antwerpen, Belgium
๐ง๐ชUniversitair Ziekenhuis Brussel /ID# 246311, Jette, Bruxelles-Capitale, Belgium
Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 50
- Registration Number
- NCT06067568
- Locations
- ๐บ๐ธ
Altasciences Clinical Los Angeles, Inc /ID# 260986, Cypress, California, United States
๐บ๐ธAcpru /Id# 259029, Grayslake, Illinois, United States
๐บ๐ธPPD Clinical Research Unit - Austin /ID# 260141, Austin, Texas, United States
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 276
- Registration Number
- NCT06063967
- Locations
- ๐ฎ๐ฑ
Bnai Zion Medical Center /ID# 264457, Haifa, Israel
๐ฏ๐ตGamagori City Hospital /ID# 261372, Gamagori-shi, Aichi, Japan
๐ฏ๐ตTsujinaka Hospital Kashiwanoha /ID# 261370, Kashiwa-shi, Chiba, Japan
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
- Conditions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06058741
- Locations
- ๐ฎ๐น
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 259535, Bologna, Emilia-Romagna, Italy
๐ฎ๐นAzienda Ospedaliero Universitaria Careggi /ID# 259766, Florence, Firenze, Italy
๐ฎ๐นA.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 258720, Torino, Piemonte, Italy
A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
- Conditions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1600
- Registration Number
- NCT06058728
- Locations
- ๐บ๐ธ
Dorsata /ID# 252675, Arlington, Virginia, United States
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT06054425
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials LLC /ID# 260740, Anaheim, California, United States
๐บ๐ธClinical Pharmacology of Miami /ID# 260800, Miami, Florida, United States
๐บ๐ธAcpru /Id# 260864, Grayslake, Illinois, United States
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 140
- Registration Number
- NCT06032546
- Locations
- ๐ต๐ท
Clinical Research Puerto Rico /ID# 256956, San Juan, Puerto Rico
๐ต๐ทHOPE Clinical Research /ID# 257487, San Juan, Puerto Rico
๐ฟ๐ฆWits RHI Research Centre /ID# 257354, Johannesburg, Gauteng, South Africa